Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 07 11 2019
accepted: 03 02 2020
pubmed: 4 4 2020
medline: 10 9 2020
entrez: 4 4 2020
Statut: ppublish

Résumé

Cytokines signaling pathway genes represent a key component of the genetic network implicated in the pathogenesis of immunoglobulin-A vasculitis (IgAV), an inflammatory vascular pathology. Interleukin (IL)17A is described as a genetic risk locus for some autoimmune diseases, such as giant cell arteritis and spondyloarthritis. Accordingly, we aimed to determine the potential influence of IL17A on the pathogenesis of IgAV. Five IL17A tag polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909), which cover the major variability of this gene, were genotyped in 360 Caucasian patients with IgAV and 1,003 sex and ethnically matched healthy controls using TaqMan probes. No statistically significant differences between patients with IgAV and healthy controls were observed when each IL17A genetic variant was analysed independently. Similarly, no statistically significant differences between patients with IgAV and healthy controls were found when the five IL17A polymorphisms were evaluated combined conforming haplotypes. In addition, there were no statistically significant differences in genotype, allele and haplotype frequencies of IL17A when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Our results do not support an influence of IL17A on the pathogenesis of IgAV.

Identifiants

pubmed: 32242803
pii: 14965

Substances chimiques

IL17A protein, human 0
Immunoglobulin A 0
Interleukin-17 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-170

Auteurs

Raquel López-Mejías (R)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain. rlopezmejias78@gmail.com.

Fernanda Genre (F)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

Sara Remuzgo-Martínez (S)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

Verónica Pulito-Cueto (V)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

Belén Sevilla-Pérez (B)

Division of Paediatrics, Hospital Universitario San Cecilio, Granada, Spain.

Javier Llorca (J)

Epidemiology and Computational Biology Department, School of Medicine, Universidad de Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain.

Norberto Ortego-Centeno (N)

Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain.

Verónica Mijares (V)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

Leticia Lera-Gómez (L)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

Maria Teresa Leonardo (MT)

Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Ana Peñalba (A)

Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

María Jesús Cabero (MJ)

Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Luis Martín-Penagos (L)

Nephrology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, Santander, Spain.

José A Miranda-Filloy (JA)

Division of Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain.

Antonio Navas Parejo (A)

Nephrology Department, Hospital Universitario San Cecilio, Granada, Spain.

Javier Sánchez Pérez (J)

Dermatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.

Diego de Argila (D)

Dermatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.

Esteban Rubio (E)

Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Manuel León Luque (M)

Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Juan María Blanco-Madrigal (JM)

Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain.

Eva Galíndez-Agirregoikoa (E)

Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain.

Javier Martín (J)

Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Granada, Spain.

Ricardo Blanco (R)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain.

Santos Castañeda (S)

Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.

Miguel A González-Gay (MA)

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and Universidad de Cantabria, Santander, Spain. miguelaggay@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH